Kiniksa Pharmaceuticals, Ltd. (KNSA)
Kiniksa Pharmaceuticals focuses on developing therapies for autoimmune and inflammatory diseases. Its lead product, ARCALYST, targets rare diseases with limited treatment options, driving revenue growth. The pipeline continues to expand across multiple indications. Chart
Akero Therapeutics, Inc. (AKRO)
Akero Therapeutics is advancing therapies for serious metabolic diseases, primarily NASH. Its lead drug candidate, efruxifermin, is in advanced clinical trials, addressing a large unmet need. The company’s innovation pipeline is a key driver of long-term potential. Chart
Pacira BioSciences, Inc. (PCRX)
Pacira BioSciences develops non-opioid pain management solutions, including EXPAREL. As demand for safer pain relief alternatives grows, Pacira’s innovative drug delivery technologies position it well in the market. Growth is fueled by surgical adoption and partnerships. Chart